Who owns drugs developed with AI?
Inventions like AI-developed drugs belong to the human inventor, says the Biotechnology Innovation Organization (BIO) in comments to the U.S. Patent and Trademark Office …
Inventions like AI-developed drugs belong to the human inventor, says the Biotechnology Innovation Organization (BIO) in comments to the U.S. Patent and Trademark Office …
U.S. Senators have been busy this week understanding and pushing forward PBM reform. On May 10, the Senate Health, Education, Labor, and Pensions (HELP) Committee …
“What scientists are telling us is that there is a reasonable chance that—God forbid—a pandemic is deadly as COVID-19 could occur in 10 years,” …
What they said at the Senate HELP hearing on PAHPA reauthorization Read More »
Exciting new therapies promise to transform medicine. But ensuring patients can access these complex treatments may require innovative payment models, says a study published …
Transformative therapies need new payment models, study finds Read More »
The Senate Health, Education, Labor, and Pension (HELP) Committee on May 2 discussed Senate Bill 1339, “The Pharmacy Benefit Manager Reform Act,” and three …
Vote on Pharmacy Benefit Manager Reform Act delayed until May 11 Read More »
Ordinary market mechanisms are inadequate against the emerging public health threat of antimicrobial resistance (AMR), lawmakers and experts agreed at the April 28 hearing …
Hearing on public health threat from AMR puts spotlight on PASTEUR Act Read More »
On April 27, a group of bipartisan U.S. Senators and U.S. Representatives reintroduced the Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act. The …
Pharmacy benefit managers (or PBMs) are in the news again as federal regulators and politicians work to shed light on the questionable and purposefully …
The Senate Finance Committee trains its sights on PBMs Read More »
The House Financial Services Committee met in a marathon session on April 26, working late into the night to consider a package of 15 …
These bills could help early-stage innovators access working capital Read More »
It is already shaping up to be a tough year for Pharmacy Benefit Managers (PBMs) as federal regulators and politicians work to shed light …